AWM
BIOL

Alterna Wealth Management’s Biolase, Inc. BIOL Stock Holding History

Alterna Wealth Management’s Portfolio BIOL Stock Details BIOL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$4K Buy
+4
New +$3.05K 0.01% 88

Other funds holding BIOL

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WPC
White Pine Capital Bloomington, Minnesota $355M AUM 45.63% 1-Year Est. Return

Alterna Wealth Management's BIOL Position: Q4 2020 in Review

Alterna Wealth Management opened a new position in Biolase, Inc. (BIOL) in Q4 2020: 4 shares worth $4K. The stake represents 0.01% of the portfolio and ranks #88 among its holdings.

29 funds tracked by Wall St. Rank hold BIOL as of Q4 2020.

  • Alterna Wealth Management held 4 shares of Biolase, Inc. worth $4K as of Q4 2020.
  • Biolase, Inc. was a new Alterna Wealth Management position in Q4 2020.
  • Biolase, Inc. made up 0.01% of Alterna Wealth Management's portfolio in Q4 2020, its #88 holding.
  • 29 funds tracked by Wall St. Rank held Biolase, Inc. as of Q4 2020.

Based on Alterna Wealth Management's 13F filing for Q4 2020, filed 11 Feb 2021.